A company that creates "Innovations, Success, and Miracles"
We revolutionize the pursuit of human well-being, the improvement of life, the promotion of health, and especially the field of drug development.
Our goal is to go beyond existing medication by developing new treatment methods that are safe and effective and by developing tailor-made medication that supports maintaining health and society's health and longevity, such as anti-aging medication for a super-aged society.
We are a company that aims to contribute to society.
To contribute to society, we will carry out the following nanovesicle businesses in cooperation with the national government, local governments, and companies, setting our goal.
- Exosome drug development-related business
- Compounded drug discovery-related business
- AI drug discovery-related business
- Antibody-related business
- Regional revitalization-related business
Contents
Topics
| Oct 13 2022 | ISM applied to amend its patented method for producing compositions containing exosomes. |
|---|---|
| Aug 03 2022 | We have successfully produced COPB2 mouse monoclonal antibodies that can be ap plied to human and animal COPB2 protein concentration measurement by ELISA, al so to Western blotting and immunostaining. |
| Jan 20 2022 | Joint Research Agreement on the Development of New Therapeutic Drugs Signed between ISM and the University of Tokyo |
| Dec 24 2021 | Joint Research Agreement on Explorational Research for New Therapeutic Drugs Signed between ISM and the University of Tokyo |
| Nov 18 2021 | Takahiro Ochiya, our Representative Director and CSO, was selected as one of the Highly Cited Researchers 2021 in Clarivate Analytics’ Web of Science. Click here for more information. |
| Oct 11 2021 | Takahiro Ochiya, our Representative Director and CSO, was interviewed in Medical Frontiers, an NHK World’s medical TV program. Click here to view the program |
| Aug 17 2021 | Yu Fujita, our scientific advisor, discovered an exosome which suppresses pulmonary fibrogenesis in our patented medical technology to cure respiratory diseases, and it was featured in The Nikkei Biotechnology & Business. Click here for more information. |
| Aug 12 2021 | Our patented technology COPB2, which enables early prediction of aggravation of the symptoms of COVID-19, was published in The Nikkei Bio. (For the development of diagnosis kits and treatment methods) |
| Aug 11 2021 | Joint Research and Development Agreement on New Treatments for Respiratory Diseases (such as COPB2) Signed between ISM and Keio University |
| Aug 03 2021 | Takahiro Ochiya, our Representative Director and CSO, and Yu Fujita, our scientific advisor, released a press release on our patented medical technology to cure respiratory diseases for the clinical application of remedy inhaler. Click here for more information. |
| Aug 01 2021 | We will co-host a luncheon seminar of the 41st meeting of the Japan Society for Molecular Tumor Marker Research at PACIFICO Yokohama on September 29. Click here for more information. |
| Apr 22 2021 | Mitsuru Miyato, our Representative Director and CEO, and Takahiro Ochiya, our Representative Director and CSO, authored a thesis entitled “Prediction of aggravation of the symptoms of patients suffering from COVID-19,” and it was recognized and highly evaluated by international organizations. Click here for more information. |
| Apr 14 2021 | We will hold the 85th Annual Meeting of the Japanese Society of Interferon & Cytokine Research from 3:20 p.m. to 4:20 p.m. on May 22. Click here for more information. |
| Mar 25 2021 | Takahiro Ochiya, our Representative Director and CSO, was interviewed for the main topic of the April 2021 issue of The People’s Daily. It introduced our remedy and business to predict aggravation of the symptoms of COVID-19. |
| Mar 25 2021 | Takahiro Ochiya, our Representative Director and CSO, was featured in the main article of The Japan New Overseas Chinese News of New China News Agency. It is an introduction to China of our remedy and business to predict aggravation of the symptoms of COVID-19. |
| Feb 22 2021 | Yu Fujita, our scientific advisor, was featured in The Nikkei for our patented new remedy for patients suffering from severe symptoms of COVID-19. Click here for more information. |
| Jan 24 2021 | As a commentator, Takahiro Ochiya, our Representative Director and CSO, participated in BS Nippon Corporation’s TV program, “Cancer and Precision Medicine,” the 3rd installment of Medical Advancement and Pharmaceutical Innovation: Yume no Medi Shinden 2021 Special. (Interview with commentators starts at 19:26.) Click here to view the program |
| Jan 10 2021 | We will hold an evening seminar in the 5th meeting of the Japanese Society for the Study of Liquid Biopsy on January 22 and 23. Click here for more information. |
| Dec 18 2020 | International Space Medical and Yamanashi Prefecture have concluded a basic agreement for searching functional components of an exosome by using fish called Fujinosuke, which is the first-ever initiative in the world. Fujinosuke is a brand of a fish originated in Yamanashi Prefecture, developed by spending dozen years on research for hybridizing king salmon and rainbow trout. Click here for more information. |
| Nov 19 2020 | Takahiro Ochiya, our Representative Director and CSO, was selected as one of the Highly Cited Researchers 2020 in Clarivate Analytics’ Web of Science. Click here for more information. |
| Oct 23 2020 | The research and development we have been conducting on the prediction of aggravation of the symptoms of COVID-19 was featured in The Town News. Click here for more information. |
| Oct 22 2020 | At the 58th annual meeting of Japan Society of Clinical Oncology, Takahiro Ochiya, our Representative Director and CSO, made a presentation entitled “Possibilities of prevention and treatment of COVID-19 by using exosomes,” where he introduced research results that exosomes can be utilized as a predictor of aggravation of the symptoms of COVID-19. Click here for more information. |
| Oct 13 2020 | Tokyo Medical University, the Jikei University and International Space Medical identified a predictor of aggravation of the symptoms of COVID-19 by using liquid biopsy. The results of this research demonstrate 100% accuracy of sensitivity and specificity. It is greatly expected that we can utilize them for predictions, development of new remedies and clarification of clinical conditions. Click here for more information. |
| Oct 13 2020 | The technology on which we have been conducting research and development for determining aggravation of the symptoms of COVID-19 by using blood protein was featured in The Nikkei. Click here for more information. |
| Sep 01 2020 | We will hold a luncheon seminar in the annual meeting of Japanese Society for Extracellular Vesicles (JSEV) 2020 on October 26 and 27. Click here for more information. |
| Aug 20 2020 | “We can stop cancer,” which was authored and edited by our Representative Director and CSO Takahiro Ochiya, was published. Click here for more information. |
| Aug 01 2020 | We have concluded a joint research agreement with the National Cancer Center for the development of oligonucleotide therapeutics and drug delivery system which are effective for cancer treatment. |
| Jul 20 2020 | Yu Fujita, our scientific advisor, wrote a paper entitled “Pursuit of new remedy for patients suffering from severe respiratory problems due to COVID-19” in regards to our patented medical technology, and it was featured in The Nikkei. Click here for more information. |
| Apr 30 2020 | Takahiro Ochiya, our Representative Director and CSO, appeared on a TV program which conveys messages from parties involved in cancer, “For Early Detection of Cancer by Using Blood RNA,” the 118th installment of Shinshu cancer project produced by Asahi Broadcasting Nagano. Click here to view the program |
| Apr 01 2020 | Takahiro Ochiya, our Representative Director and CSO, received the Princess Takamatsu Cancer Research Fund Prizes from the Princess Takamatsu Cancer Research Fund for his development and practical application of an early diagnostic method of cancer by using microRNA in body fluid. Click here for more information. |
| Dec 19 2019 | Takahiro Ochiya, our Representative Director and CSO, was selected as one of the Highly Cited Researchers 2019 in Clarivate Analytics’ Web of Science. Click here for more information. |
| Oct 25 2019 | The research team in which Takahiro Ochiya, our Representative Director and CSO, and Juntaro Matsuzaki, our scientific advisor, participate succeeded in the production of human liver progenitor cell, leading to the establishment of a core strategic technology for the new treatment method of liver diseases. Click here for more information. |
| Aug 17 2018 | Our patent on the detection method of colon cancer was registered. |
| Aug 01 2018 | Takahiro Ochiya, our Representative Director and CSO, discovered the world’s first method for detecting cancers at an early stage with blood, which was featured in The Nikkei. Click here for more information. |
| Jul 22 2018 | An NHK’s TV program “Science Zero” featured Takahiro Ochiya, our Representative Director and CSO, in “Exosomes, fundamentals for life support.” Click here to view the program |
| Jul 19 2017 | Our patent on testing the possibility of pancreatic cancer was registered. |
| Nov 11 2016 | Takahiro Ochiya, our Representative Director and CSO, succeeded in the rejuvenation of hepatocyte via animal experiment, which was featured in The Nikkei. Click here for more information. |
| Jul 14 2016 | As a projector, Takahiro Ochiya, our Representative Director and CSO, participated in Experimental Medicine’s article (June 2016 issue; published by Yodosha), “A messenger with a 100-nm diameter: Can exosomes bring about innovations for diagnosis and treatment?” Click here for more information. |